<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02704494</url>
  </required_header>
  <id_info>
    <org_study_id>93-01-49-9028</org_study_id>
    <nct_id>NCT02704494</nct_id>
  </id_info>
  <brief_title>Resveratrol's Effects in Diabetic Nephropathy</brief_title>
  <acronym>ReDNeph</acronym>
  <official_title>Resveratrol's Effects in Diabetic Nephropathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shiraz University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shiraz University of Medical Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to evaluate the safety and effects of resveratrol in treatment of&#xD;
      diabetic nephropathy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Diabetes mellitus (DM) is one of the most important public health burdens, and its prevalence&#xD;
      has rapidly increased worldwide over the past decades. One of the most important&#xD;
      complications of DM is nephropathy.&#xD;
&#xD;
      Resveratrol (3, 5, 4'-trihydroxystilbene) is a natural polyphenolic compound belongs to the&#xD;
      large group of polyphenols found in different plant species. The richest natural source of&#xD;
      resveratrol is Polygonum cuspidatum - a plant root extract of which have been used in&#xD;
      oriental folk medicine. Considerable amounts of resveratrol were also found in skin of red&#xD;
      grapes, peanuts, groundnuts, and red vine.&#xD;
&#xD;
      Resveratrol is considered to have beneficial effects on glucose tolerance and insulin&#xD;
      sensitivity, the cardiovascular system, as it has been found to improve vasodilatation,&#xD;
      ischaemic preconditioning, both of which seem to be the result of the activation of the&#xD;
      endothelial NO synthase enzyme, and to inhibit both platelet aggregation and vascular smooth&#xD;
      muscle cell proliferation. Resveratrol itself is an efficient antioxidant, as evidenced by&#xD;
      both in vitro and in vivo studies, and, it has also been shown to improve diabetes-related&#xD;
      impairments in animals.&#xD;
&#xD;
      We hypothesized that resveratrol may have a favorable effects on control of diabetic&#xD;
      nephropathy. The aim of this study is to evaluate the safety and effects of resveratrol in&#xD;
      treatment of diabetic nephropathy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 2016</start_date>
  <completion_date type="Actual">February 2017</completion_date>
  <primary_completion_date type="Actual">February 2017</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Urine albumin level</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum creatinin</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fasting blood sugar (FBS)</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glycosylated hemoglobin (A1C)</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Liver aminotransferases (ALT and AST)</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum insulin level</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with adverse events</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Diabetic Nephropathy</condition>
  <arm_group>
    <arm_group_label>Resveratrol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Resveratrol + Losartan</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo + Losartan</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Resveratrol</intervention_name>
    <description>Resveratrol 500mg daily</description>
    <arm_group_label>Resveratrol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo 1 capsule daily</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Losartan</intervention_name>
    <description>Losartan 12.5mg daily</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Resveratrol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Type 2 diabetes mellitus (DM)&#xD;
&#xD;
          -  Controlled blood sugar [fasting blood sugar (FBS) &lt;130mg/dl and glycosylated&#xD;
             hemoglobin (A1C)&lt;7%&#xD;
&#xD;
          -  Urine albumin &gt;20mg/lit in two separate occasions during the last 3 months period&#xD;
&#xD;
          -  Serum creatinin &lt; or = 2mg/dl&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Lactation&#xD;
&#xD;
          -  Alcoholism&#xD;
&#xD;
          -  Liver failure (acute or chronic)&#xD;
&#xD;
          -  Renal failure: serum creatinin &gt;2mg/dl&#xD;
&#xD;
          -  Glomerulonephritis&#xD;
&#xD;
          -  Uncontrolled hypertension&#xD;
&#xD;
          -  Congestive heart failure&#xD;
&#xD;
          -  Prostate disease&#xD;
&#xD;
          -  Malignancy&#xD;
&#xD;
          -  Bilateral renal artery stenosis&#xD;
&#xD;
          -  Any systemic disease other than DM&#xD;
&#xD;
          -  Any infection or rheumatologic disorder&#xD;
&#xD;
          -  Use of warfarin&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gholamhossein Ranjbar Omrani, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Endocrine and Metabolism Research Center, Shiraz University of Medical Sciences</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jamshid Roozbeh, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shiraz Nephrology and Urology Research Center, Shiraz University of Medical Sciences</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Azar Sattarinejad, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Endocrine and Metabolism Research Center, Shiraz University of Medical Sciences</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mesbah Shams, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Endocrine and Metabolism Research Center, Shiraz University of Medical Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Shahid Motahhari Clinic, Shiraz University of Medical Sciences</name>
      <address>
        <city>Shiraz</city>
        <state>Fars</state>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <study_first_submitted>March 4, 2016</study_first_submitted>
  <study_first_submitted_qc>March 6, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 10, 2016</study_first_posted>
  <last_update_submitted>October 3, 2017</last_update_submitted>
  <last_update_submitted_qc>October 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shiraz University of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Mesbah Shams, MD</investigator_full_name>
    <investigator_title>Associate professor of internal medicine and endocrinology</investigator_title>
  </responsible_party>
  <keyword>Resveratrol</keyword>
  <keyword>Diabetes mellitus</keyword>
  <keyword>Diabetes complications</keyword>
  <keyword>Diabetic nephropathies</keyword>
  <keyword>Proteinuria</keyword>
  <keyword>Albuminuria</keyword>
  <keyword>renal insufficiency</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Diabetic Nephropathies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Losartan</mesh_term>
    <mesh_term>Resveratrol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

